IP Library › Granted Patent US 10,351,547

Granted Patent B2

US 10,351,547 · App. 15/849,409 · Granted Jul 16, 2019

Somatostatin modulators and uses thereof

Inventors: Jian Zhao (San Diego, CA); Sangdon Han (San Diego, CA); Sun Hee Kim (San Diego, CA); Shimiao Wang (San Diego, CA); Yunfei Zhu (San Diego, CA)

Assignee: CRINETICS PHARMACEUTICALS, INC.

C07D401/04 C07D401/14 C07D405/14 C07D413/14 C07D471/04 C07D498/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,351,547
App. No.: 15/849,409
Granted: Jul 16, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Claims (184)

1. A compound that has the structure of Formula (A), or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:

wherein:

R A is an unsubstituted or substituted ring A that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, unsubstituted or substituted bicyclic carbocycle, or unsubstituted or substituted bicyclic heterocycle, wherein if ring A is substituted then ring A is substituted with m R a and n R b ;

each R a and R b is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —OR 14 , —O 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , —SO 2 N(R 15 ) 2 , or —C(═NOR 15 )R 15 ;

m is 1 or 2; n is 0, 1 or 2;

or if one R a and one R b are on adjacent atoms of ring A then the adjacent R a and R b groups are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 5- or 6-membered monocyclic carbocycle or an unsubstituted or substituted 5- or 6-membered monocyclic heterocycle;

R B is an unsubstituted or substituted ring B that is an unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, unsubstituted or substituted bicyclic carbocycle, or unsubstituted or substituted bicyclic heterocycle, wherein if the ring B is substituted then the ring B is substituted with p R c and q R d ;

each R c and R d is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —OR 14 , —C(═O)R 15 , —OC(═O)R 15 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —OC(═O)N(R 15 ) 2 , —NR 15 C(═O)N(R 15 ) 2 , —NR 15 C(═O)OR 14 , —NR 15 C(═O)NR 15 OR 14 , —C(═O)NR 15 OR 15 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(O)R 14 , —SO 2 R 14 , —SO 2 N(R 15 ) 2 , —C(═NOR 15 )R 15 , —N(R 15 )SO 2 R 14 , —C(═O)NR 15 S(═O) 2 R 14 , —S(═O) 2 NR 15 C(═O)R 14 , —C(═NR 15 )N(R 15 ) 2 , —NR 15 C(═NR 15 )N(R 15 ) 2 , —NR 15 C(═CR 14 R 15 )N(R 15 ) 2 , —C(═O)NR 15 C(═NR 15 )N(R 15 ) 2 , or —C(═O)NR 15 C(CR 14 R 15 )N(R 15 ) 2 ;

p is 1 or 2; q is 0, 1 or 2;

or if one R c and one R d are on adjacent atoms of ring B then the adjacent R c and R d groups are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 5- or 6-membered monocyclic carbocycle or an unsubstituted or substituted 5- or 6-membered monocyclic heterocycle;

X is CR f or N;

Y is CR f or N;

Z is CR f or N;

R e is hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, —CN, —OH, —OR 14 , —CO 2 R 15 , —C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , or —SO 2 N(R 15 ) 2 ;

each R f is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, —CN, —OH, —OR 14 , —CO 2 R 15 , —C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , or —SO 2 N(R 15 ) 2 ;

R 1 and R 2 are independently hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, or substituted or unsubstituted C 2 -C 6 heterocycloalkyl;

or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form ring C that is an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl;

R 3 and R 5 are each independently selected from the group consisting of hydrogen, halogen, —OH, —OR 14 , —SR 14 , —S(═O)R 14 , —S(═O) 2 R 14 , —N(R 15 ) 2 , —CN, —C(═O)OR 15 , —C(═O)N(R 15 ) 2 , unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, and unsubstituted or substituted C 1 -C 6 fluoroalkyl;

or R 3 and R 5 are taken together to form a bond or C 1 -C 2 alkylene;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 4-7 membered saturated N-containing heterocyclic ring;

R 4 and R 6 are each independently selected from the group consisting of hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, and unsubstituted or substituted C 1 -C 6 fluoroalkyl;

R 7 is hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted C 1 -C 6 fluoroalkyl;

or R 2 and R 7 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl;

L 1 is absent or —CR 8 R 9 —;

L 2 is —CR 10 R 11 — or absent;

L 3 is —(CR 12 R 13 ) t — or absent;

t is 1 or 2;

each R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 is independently selected from the group consisting of hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, and unsubstituted or substituted C 1 -C 6 fluoroalkyl;

or R 5 and R 8 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic carbocyclic or unsubstituted or substituted monocyclic heterocyclic ring;

or R 5 and R 13 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic carbocyclic or unsubstituted or substituted monocyclic heterocyclic ring;

or R 7 and R 8 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic carbocyclic or unsubstituted or substituted monocyclic heterocyclic ring;

each R 14 is independently selected from unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 10 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and

each R 15 is independently selected from hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted C 3 -C 10 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

or two R 15 on the same N atom are taken together with the N atom to which they are attached to form an unsubstituted or substituted N-containing heterocycle;

wherein each substituted alkyl, substituted fluoroalkyl, substituted heteroalkyl, substituted carbocycle, and substituted heterocycle is substituted with one or more R s groups independently selected from the group consisting of halogen, C 1 -C 6 alkyl, monocyclic carbocycle, monocyclic heterocycle, —CN, —OR 16 , —CO 2 R 16 , —C(═O)N(R 16 ) 2 , —N(R 16 ) 2 , —NR 16 C(O)R 17 , —SR 16 , —S(═O)R 17 , —SO 2 R 17 , and —SO 2 N(R 16 ) 2 ;

each R 16 is independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, benzyl, 5-membered heteroaryl, and 6-membered heteroaryl; or two R 16 groups are taken together with the N atom to which they are attached to form a N-containing heterocycle; and

each R 17 is independently selected from C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, benzyl, 5-membered heteroaryl, and 6-membered heteroaryl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl;

R 4 and R 6 are each independently selected from the group consisting of hydrogen and —CH 3 ;

R 7 is hydrogen, —CH 3 , or —CH 2 CH 3 ;

or R 2 and R 7 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl; and

each R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 is independently selected from the group consisting of hydrogen and —CH 3 .

3. The compound of claim 2 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

X is CR f ; Y is CR f ; and Z is CR f ;

or X is N; Y is CR f ; and Z is CR f ;

or X is CR f ; Y is N; and Z is CR f ;

or X is CR f ; Y is CR f ; and Z is N;

or X is N; Y is N; and Z is CR f ;

or X is CR f ; Y is N; and Z is N;

or X is N; Y is N; and Z is N;

L 1 is absent, —CH 2 —, —CHCH 3 —, or —CH(CH 2 CH 3 )—;

L 2 is —CH 2 — or absent; and

L 3 is —CH 2 —, CH 2 CH 2 —, or absent.

4. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R e is hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, —CN, —OH, or —OR 14 ; and

each R f is independently hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, —CN, —OH, or —OR 14 .

5. The compound of claim 4 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R A is an unsubstituted or substituted ring A that is an unsubstituted or substituted phenyl, an unsubstituted or substituted monocyclic 5- or 6-membered heteroaryl containing 1-4 N atoms and 0 or 1 O or S atom, or an unsubstituted or substituted monocyclic 5- or 6-membered heteroaryl containing 0-4 N atoms and 1 O or S atoms; and

R B is an unsubstituted or substituted ring B that is an unsubstituted or substituted phenyl, unsubstituted or substituted monocyclic 5- or 6-membered heteroaryl containing 1-4 N atoms and 0 or 1 O or S atom, or unsubstituted or substituted monocyclic heteroaryl containing 0-4 N atoms and 1 O or S atoms.

6. The compound of claim 4 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R A is an unsubstituted or substituted ring A that is an unsubstituted or substituted phenyl, unsubstituted or substituted furanyl, unsubstituted or substituted pyrrolyl, unsubstituted or substituted oxazolyl, unsubstituted or substituted thiazolyl, unsubstituted or substituted imidazolyl, unsubstituted or substituted pyrazolyl, unsubstituted or substituted triazolyl, unsubstituted or substituted tetrazolyl, unsubstituted or substituted isoxazolyl, unsubstituted or substituted isothiazolyl, unsubstituted or substituted oxadiazolyl, unsubstituted or substituted thiadiazolyl, unsubstituted or substituted pyridinyl, unsubstituted or substituted pyrimidinyl, unsubstituted or substituted pyrazinyl, unsubstituted or substituted pyridazinyl, or unsubstituted or substituted triazinyl; and

R B is an unsubstituted or substituted ring B that is an unsubstituted or substituted phenyl, unsubstituted or substituted furanyl, unsubstituted or substituted pyrrolyl, unsubstituted or substituted oxazolyl, unsubstituted or substituted thiazolyl, unsubstituted or substituted imidazolyl, unsubstituted or substituted pyrazolyl, unsubstituted or substituted triazolyl, unsubstituted or substituted tetrazolyl, unsubstituted or substituted isoxazolyl, unsubstituted or substituted isothiazolyl, unsubstituted or substituted oxadiazolyl, unsubstituted or substituted thiadiazolyl, unsubstituted or substituted pyridinyl, unsubstituted or substituted pyrimidinyl, unsubstituted or substituted pyrazinyl, unsubstituted or substituted pyridazinyl, or unsubstituted or substituted triazinyl.

7. A compound that has the following structure, or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:

wherein:

each R a and R b is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted C 1 -C 6 heteroalkyl, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —OR 14 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —CH 2 C(═O)N(R 15 ) 2 , —NR 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , —SO 2 N(R 15 ) 2 , or —C(═NOR 15 )R 15 ;

m is 1 or 2; n is 0, 1 or 2;

R B is an unsubstituted or substituted ring B that is an unsubstituted or substituted phenyl, or an unsubstituted or substituted pyridinyl, wherein if the ring B is substituted then the ring B is substituted with p R c and q R d ;

each R c and R d is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted monocyclic carbocycle, unsubstituted or substituted monocyclic heterocycle, —CN, —OH, —OR 14 , —C(═O)R 15 , —OC(═O)R 15 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —OC(═O)N(R 15 ) 2 , —NR 15 C(═O)N(R 15 ) 2 , —NR 15 C(═O)OR 14 , NR 15 C(═O)NR 15 OR 14 , —C(═O)NR 15 OR 15 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(═O) 2 R 14 , —SO 2 R 14 , —SO 2 N(R 15 ) 2 , —C(═NOR 15 )R 15 , —N(R 15 )SO 2 R 14 , —C(═O)NR 15 S(═O) 2 R 14 , —S(═O) 2 NR 15 C(═O)R 14 , —C(═NR 15 ) 2 , —NR 15 C(═NR 15 )N(R 15 ) 2 , —NR 15 C(═CR 14 R 15 )N(R 15 ) 2 , —C(═O)NR 15 C(═NR 15 )N(R 15 ) 2 , or —C(═O)NR 15 C(═CR 14 R 15 )N(R 15 ) 2 ;

p is 1 or 2; q is 0, 1 or 2;

X is CR f or N;

Y is CR f or N;

Z is CR f or N;

R e is hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, —CN, —OH, or —OR 14 ;

each R f is independently hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, —CN, —OH, or —OR 14 ;

or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form ring C that is an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl;

or R 3 and R 5 are taken together to form a bond or C 1 -C 2 alkylene;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 4-7 membered saturated N-containing heterocyclic ring;

R 7 is hydrogen or unsubstituted or substituted C 1 -C 4 alkyl;

or R 2 and R 7 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted N-containing C 2 -C 8 heterocycloalkyl;

L 1 is absent or —CHR 8 —;

L 2 is —CH 2 — or absent;

L 3 is —CH 2 —, —CH 2 CH 2 —, or absent;

R 8 is hydrogen or C 1 -C 4 alkyl;

or two R 15 on the same N atom are taken together with the N atom to which they are attached to form an unsubstituted or substituted N-containing heterocycle;

wherein each substituted alkyl, substituted fluoroalkyl, substituted heteroalkyl, substituted carbocycle, and substituted heterocycle is substituted with one or more R s groups independently selected from the group consisting of halogen, C 1 -C 6 alkyl, monocyclic carbocycle, monocyclic heterocycle, —CN, —OR 16 , —CO 2 R 16 , —C(═O)N(R 16 ) 2 , —N(R 16 ) 2 , —NR 16 C(═O)R 17 , —SR 16 , —S(═O)R 17 , —SO 2 R 17 , and —SO 2 N(R 16 ) 2 ;

each R 17 is independently selected from C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, benzyl, 5-membered heteroaryl, and 6-membered heteroaryl.

8. The compound of claim 7 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R B is

9. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R a is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 heteroalkyl, —CN, —OH, —OR 14 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , or —SO 2 N(R 15 ) 2 ; and

each R b is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted C 1 -C 4 heteroalkyl, —CN, —OH, or —O-(unsubstituted or substituted C 1 -C 4 alkyl).

10. The compound claim 8 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R c is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 fluoroalkyl, —CN, —OH, —OR 14 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —NR 15 C(═O)NR 15 OR 14 , —C(═O)NR 15 OR 15 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SR 14 , —S(═O)R 14 , —SO 2 R 14 , —SO 2 N(R 15 ) 2 , or N(R 15 )SO 2 R 14 ; and

R d is independently hydrogen, halogen, unsubstituted or substituted C 1 -C 4 alkyl, unsubstituted or substituted C 1 -C 4 fluoroalkyl, unsubstituted or substituted monocyclic 4-7-membered heterocycle, —CN, —OH, —O-(unsubstituted or substituted C 1 -C 4 alkyl), —O-(unsubstituted or substituted C 1 -C 4 heteroalkyl), —C(═O)R 15 , —OC(═O)R 15 , —CO 2 R 15 , —CH 2 CO 2 R 15 , —C(═O)N(R 15 ) 2 , —OC(═O)N(R 15 ) 2 , —NR 15 C(═O)N(R 15 ) 2 , —NR 15 C(═O)OR 14 , —NR 15 C(═O)NR 15 OR 14 , —C(═O)NR 15 OR 15 , —CH 2 C(═O)N(R 15 ) 2 , —N(R 15 ) 2 , —CH 2 N(R 15 ) 2 , —CH(CF 3 )N(R 15 ) 2 , —NR 15 C(═O)R 14 , —CH 2 NR 15 C(═O)R 14 , —SO 2 N(R 15 ) 2 , —C(═NOR 15 )R 15 , —N(R 15 )SO 2 R 14 , —C(═O)NR 15 S(═O) 2 R 14 , —S(═O) 2 NR 15 C(═O)R 14 , or —C(═NR 15 )N(R 15 ) 2 ;

11. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R a is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —C(CH 3 ) 3 , —CH 2 OH, —CH 2 CN, —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCH 2 CH 3 , —OCF 3 , —CH 2 CH 2 OH, —CO 2 H, —CO 2 CH 3 , —CO 2 CH 2 CH 3 , —CH 2 CO 2 H, —CH 2 CO 2 CH 3 , —CH 2 CO 2 CH 2 CH 3 , —C(═O)NH 2 , —C(═O)NHCH 3 , —C(═O)N(CH 3 ) 2 , —CH 2 C(═O)NH 2 , —CH 2 C(═O)NHCH 3 , —CH 2 C(═O)N(CH 3 ) 2 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —CH 2 NH 2 , —CH 2 NHCH 3 , or —CH 2 N(CH 3 ) 2 ;

each R b is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —C(CH 3 ) 3 , —CH 2 OH, —CH 2 CN, —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCH 2 CH 3 , or —OCF 3 ;

each R c is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —C(CH 3 ) 3 , —CH 2 OH, —CH 2 CN, —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCH 2 CH 3 , —OCF 3 , —CO 2 H, —CO 2 CH 3 , —CO 2 CH 2 CH 3 , —CH 2 CO 2 H, —CH 2 CO 2 CH 3 , —CH 2 CO 2 CH 2 CH 3 , —C(═O)NH 2 , —C(═O)NHCH 3 , —C(═O)NHOCH 3 , —C(═O)N(CH 3 ) 2 , —SO 2 N(CH 3 ) 2 , —C(═NOCH 3 )H, —CH 2 C(═O)NH 2 , —CH 2 C(═O)NHCH 3 , —CH 2 C(═O)N(CH 3 ) 2 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NHCO 2 CH 3 , —NHSO 2 CH 3 , —CH 2 NH 2 , —CH 2 NHCH 3 , —CH 2 N(CH 3 ) 2 , CH(CF 3 )NH 2 , azetidinyl, or pyrrolidinyl; and

each R d is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —C(CH 3 ) 3 , —CH 2 OH, —CH 2 CN, —CH 2 F, —CHF 2 , —CF 3 , pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, —CN, —OH, —OCH 3 , —OCH 2 CH 3 , —OCF 3 , —OCH 2 OCH 3 , —OCH 2 OCH 2 CH 3 , —OCH 2 CH 2 OH, —C(═O)NHOCH 3 , —C(═NOH)H, —C(═NOCH 3 )H, —CH 2 C(═O)NH 2 , —NH 2 , NHCO 2 CH 3 , NHSO 2 CH 3 , NH(C═O)NHCH 3 , NH(C═O)NHOCH 3 , CH(CF 3 )NH 2 ;

12. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R a is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCF 3 , —CH 2 OH or —CH 2 CH 2 OH;

each R b is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCF 3 ;

each R c is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, —CN, —OH, —OCH 3 , —OCF 3 , —NH 2 , —C(═O)NH 2 , —C(═NOH)H, —C(═NOCH 3 )H, —SO 2 CH 3 , —SO 2 N(CH 3 ) 2 , azetidinyl, or pyrrolidinyl; and

each R d is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCF 3 , —OCH 2 OCH 3 , —CH 2 OH, —OCH 2 CH 2 OH, —C(═O)NH 2 , —C(═O)NHOCH 3 , NH 2 , —NHCO 2 CH 3 , —NH(C═O)NHOCH 3 , or —CH 2 (C═O)NH 2 ;

13. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

X is CR f ; Y is CR f ; and Z is CR f ;

or X is N; Y is CR f ; and Z is CR f ;

or X is CR f ; Y is N; and Z is CR f ;

or X is CR f ; Y is CR f ; and Z is N;

or X is N; Y is N; and Z is CR f ;

or X is CR f ; Y is N; and Z is N;

or X is N; Y is N; and Z is N;

L 1 is absent, —CH 2 —, —CH(CH 3 )—, or —CH(CH 2 CH 3 )—; and

L 2 is —CH 2 —; and L 3 is —CH 2 —;

or L 2 is absent; and L 3 is —CH 2 CH 2 —;

or L 2 is absent; and L 3 is absent;

or L 2 is absent; and L 3 is —CH 2 —.

14. The compound of claim 13 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 1 hydrogen;

R 2 is hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 fluoroalkyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, or substituted or unsubstituted C 2 -C 6 heterocycloalkyl;

or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form ring C that is an unsubstituted or substituted N-containing C 2 -C 6 heterocycloalkyl;

R 3 is hydrogen;

R 5 is selected from the group consisting of hydrogen, halogen, —OH, —OR 14 , —S(═O) 2 R 14 , —N(R 15 ) 2 , —CN, —C(═O)OR 15 , —C(═O)N(R 15 ) 2 , unsubstituted or substituted C 1 -C 6 alkyl, and unsubstituted or substituted C 1 -C 6 fluoroalkyl;

or R 3 and R 5 are taken together to form a bond, —CH 2 —, or —CH 2 CH 2 —;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 4- to 7-membered saturated N-containing heterocyclic ring; and

R 7 is hydrogen or C 1 -C 4 alkyl;

or R 2 and R 7 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted 4- to 7-membered N-containing heterocycloalkyl.

15. The compound of claim 13 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 1 hydrogen;

R 2 is hydrogen, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 OH, —CH 2 CH 2 OCH 3 , —CH 2 CH 2 F, —CH 2 CH 2 NH 2 , —CH 2 CH 2 NHCH 3 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , cyclopropyl, —CH 2 CH 2 CH 2 F, —CH 2 CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OCH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH(CH 3 )(CH 2 CH 3 ), —C(CH 3 ) 3 , cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl;

or R 1 and R 2 are taken together with the nitrogen atom to which they are attached to form ring C that is an unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, unsubstituted or substituted piperazinyl, or unsubstituted or substituted azepanyl;

R 3 is hydrogen;

R 5 is hydrogen, F, Cl, Br, —OH, —OCH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OCH 2 CH 3 , —OCF 3 , —CH 3 , —CH 2 CH 3 , —CH 2 F, —CHF 2 , —CF 3 —CN, —C(═O)OCH 3 , —C(═O)NH 2 , —C(═O)NHCH 3 , or —C(═O)N(CH 3 ) 2 ;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, unsubstituted or substituted piperazinyl, or unsubstituted or substituted azepanyl; and

R 7 is hydrogen, —CH 3 , or —CH 2 CH 3 ;

or R 2 and R 7 are taken together with the nitrogen atom to which they are attached to form an unsubstituted or substituted monocyclic 4- to 7-membered heterocyclic ring selected from unsubstituted or substituted azetidinyl, unsubstituted or substituted pyrrolidinyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, unsubstituted or substituted piperazinyl, or unsubstituted or substituted azepanyl.

16. The compound of claim 13 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

17. The compound of claim 13 , wherein the compound has the following structure, or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof:

18. The compound of claim 17 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 1 is hydrogen; and

R 2 is hydrogen, methyl, ethyl, 2-fluoroethyl, 2-hydroxyethyl, 2-methoxyethyl, n-propyl, i-propyl, cyclopropyl, 3-fluoropropyl, 3-methoxypropyl, n-butyl, i-butyl, sec-butyl, cyclobutyl, or tert-butyl, or oxetanyl.

19. The compound of claim 17 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R 1 is hydrogen; and

R 2 is hydrogen.

20. The compound of claim 17 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

each R a is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCF 3 , —CH 2 OH or —CH 2 CH 2 OH;

each R b is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , or —OCF 3 ;

each R d is independently hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , —OCF 3 , —OCH 2 OCH 3 , —CH 2 OH, —OCH 2 CH 2 OH, —C(═O)NH 2 , —C(═O)NHOCH 3 , —NH 2 , —NHCO 2 CH 3 , —NH(C═O)NHOCH 3 , —CH 2 (C═O)NH 2 ;

R e is hydrogen, F, Cl, Br, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —OH, —OCH 3 , or —OCF 3 ;

R 1 hydrogen;

R 2 is hydrogen; and

R 5 is hydrogen, F, Cl, Br, —OH, —OCH 3 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —OCH 2 CH 3 , —OCF 3 , —CH 3 , —CH 2 CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CN, —C(═O)OCH 3 , —C(═O)NH 2 , —C(═O)NHCH 3 , or —C(═O)N(CH 3 ) 2 ;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted monocyclic 6-membered heterocyclic ring selected from unsubstituted or substituted piperidinyl, unsubstituted or substituted morpholinyl, unsubstituted or substituted thiomorpholinyl, or unsubstituted or substituted piperazinyl.

21. The compound of claim 20 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, wherein:

R a is independently hydrogen, F, Cl, —CH 3 , —CF 3 , —CN, —OH, —CH 2 OH, —CH 2 CH 2 OH, —OCH 3 , or —OCF 3 ,

R b is independently hydrogen, F, Cl, —CH 3 , —CF 3 , —CN, —OH, —OCH 3 , or —OCF 3 ;

each R c is independently hydrogen, F, Cl, —CH 3 , —CF 3 , —CN, —OH, —OCH 3 , —NH 2 , —C(═O)NH 2 , —C(═NOH)H, or —C(═NOCH 3 )H;

each R d is independently hydrogen, F, Cl, —CH 3 , —CF 3 , —CN, —OH, —NH 2 , —OCH 3 , or —OCF 3 ;

X is CR f ; Y is CR f ; and Z is CR f ;

or X is N; Y is CR f ; and Z is CR f ;

or X is CR f ; Y is N; and Z is CR f ;

or X is CR f ; Y is CR f ; and Z is N;

R 1 hydrogen;

R 2 is hydrogen; and

R 5 is hydrogen;

or R 2 and R 5 are taken together with the intervening atoms to which they are attached to form an unsubstituted or substituted morpholinyl.

22. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, and at least one pharmaceutically acceptable excipient.

23. A method of modulating somatostatin receptor subtype 2 (SSTR2) activity in a mammal comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, to the mammal in need thereof.

24. A method of treating acromegaly, a neuroendocrine tumor, pain, or combinations thereof in a mammal comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, diastereomeric mixture, or individual enantiomers thereof, to the mammal in need thereof.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018

From: ZHAO, JIAN; HAN, SANGDON; KIM, SUN HEE; WANG, SHIMIAO; ZHU, YUNFEI

To: CRINETICS PHARMACEUTICALS, INC.

Reel/Frame 045626/0027 →

Continuity (4)

Continuation 15647758 · Jul 12, 2017

Provisional Application 62362493 · Jul 14, 2016

Provisional Application 62411338 · Oct 21, 2016

Related Publication 20190002431A1 · Jan 3, 2019

Cited By (2)

US 12,208,092 US 12,617,767